[go: up one dir, main page]

GT200000104A - POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS. - Google Patents

POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.

Info

Publication number
GT200000104A
GT200000104A GT200000104A GT200000104A GT200000104A GT 200000104 A GT200000104 A GT 200000104A GT 200000104 A GT200000104 A GT 200000104A GT 200000104 A GT200000104 A GT 200000104A GT 200000104 A GT200000104 A GT 200000104A
Authority
GT
Guatemala
Prior art keywords
diclorhydrate
polymorphes
crystalline
azobiciclo
ilamine
Prior art date
Application number
GT200000104A
Other languages
Spanish (es)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Michael Jon Gumkowski
David Josiph Muehlbauer
Timothy Norris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to GT200000104A priority Critical patent/GT200000104A/en
Publication of GT200000104A publication Critical patent/GT200000104A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DOS FORMAS POLIMORFICAS CRISTALINAS DEL DICLORHIDRATO DE (2BENCIDRIL1AZOBICICLO [2.2.2]OCT3IL) (5 ISOPROPIL 2 METOXIBENCIL) AMINA DIHIDRATADO SON LA FORMA I Y LA FORMA II. LA COMPOSICION FARMACEUTICA QUE CONTIENE POR LO MENOS UNO DE ESTOS POLIMORFOS PRESENTA UNA ESTABILIDAD VENTAJOSA (EL COMPUESTO PURO ES HIDRATABLE) PARA PREPARAR UNA FORMULACION DESTINADA A TRATAR LA EMESIS EN PACIENTES QUE RECIBEN QUIMIOTERAPIA. LA ADMINISTRACION DE ESTA COMPOSICION FARMACEUTICA ES ORAL CONVENCIONAL, PREFERIBLEMENTE MEDIANTE COMPRIMIDOS O CAPSULAS, O INTRAVENOSA. EL COMPUESTO ES UN ANTAGONISTA DE RECEPTORES ACTIVOS NK 1 DEL SNC Y SE REFIERE AL TRATAMIENTO DE DOLENCIAS FACILITADAS POR UNA DISMINUCION DE LA NEUROTRANSMISION MEDIADA POR LA SUSTANCIA P.TWO CRYSTALLINE POLYMORPHIC FORMS OF THE (2BENCIDRIL1AZOBICICLO [2.2.2] OCT3IL) DICLORHYDRATE (5 ISOPROPIL 2 METOXIBENCIL) AMINE DIHYDRATE ARE FORM I AND FORM II. THE PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE OF THESE POLYMORPHES PRESENTS AN ADVANTAGE STABILITY (THE PURE COMPOUND IS HYDRATIONABLE) TO PREPARE A FORMULATION INTENDED TO TREAT EMESIS IN PATIENTS RECEIVING CHEMOTHERAPY. THE ADMINISTRATION OF THIS PHARMACEUTICAL COMPOSITION IS CONVENTIONAL ORAL, PREFERIBLY THROUGH COMPRESSED OR CAPSULES, OR INTRAVENOUS. THE COMPOUND IS AN ANCEGONIST OF ACTIVE RECEIVERS NK 1 OF THE SNC AND REFERS TO THE TREATMENT OF DOLENCES PROVIDED BY A DECREASE OF THE NEUROTRANSMISSION MEDIATION BY THE SUBSTANCE P.

GT200000104A 2000-06-28 2000-06-28 POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS. GT200000104A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GT200000104A GT200000104A (en) 2000-06-28 2000-06-28 POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GT200000104A GT200000104A (en) 2000-06-28 2000-06-28 POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.

Publications (1)

Publication Number Publication Date
GT200000104A true GT200000104A (en) 2001-12-20

Family

ID=47043927

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000104A GT200000104A (en) 2000-06-28 2000-06-28 POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.

Country Status (1)

Country Link
GT (1) GT200000104A (en)

Similar Documents

Publication Publication Date Title
DK0954314T3 (en) Dosage forms for ameliorating male erectile dysfunction
DE60038183D1 (en) COMPOUNDS AND COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS
AR025959A1 (en) DERIVATIVES OF TER.-BUTIL- (7-METHYL-IMIDAZO [1,2, a] PIRIDIN-3-IL) -AMINA, PROCEDURE FOR THEIR PREPARATION, DRUGS THAT CONTAIN THEM, THEIR USE FOR THE PREPARATION OF A MEDICATION FOR THE INHIBITION OF NON-SYNTHEASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GT199900203A (en) CELECOXIB COMPOSITIONS.
AR028833A1 (en) INHIBITING METALOPROTEASE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, USE FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHOD AND PROCEDURE FOR PREPARATION
ES2091649T3 (en) USE OF RIFAXIMINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT IN THE TREATMENT OF GASTRIC DYSPEPSIA CAUSED BY HELICOBACTER PYLORI.
SV2002000696A (en) IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PC9985AHXK / BB
CL2009001682A1 (en) Spontaneously dispersible pharmaceutical composition for oral administration comprising n-benzoyl-staurosporine; method to increase levels of bioavailability. (divisional of only 333-00).
PA8465901A1 (en) NEW DERIVATIVES OF ERYTHROMYCIN
BR0015605A (en) Composition and use
AR024118A1 (en) BICYCLE OXAZOLIDINONE COMPOUND AS ANTIBACTERIAL AGENTS, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR024411A1 (en) POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO [2.2.2] OCT-3-ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
AR035553A1 (en) CRYSTAL FORMS OF MELAGATRAN, PROCESS FOR ITS PRODUCTION, PHARMACEUTICAL FORMULATION, AND USE OF THIS COMPOUND IN THE DEVELOPMENT OF MEDICINES.
UY26176A1 (en) POLYMORPHIC FORMS OF A AZOBICICLO CITRATE (2,2,2) OCTAN-3-AMINE AND ITS PHARMACEUTICAL COMPOSITIONS.
GT200000104A (en) POLYMORPHES OF A CRYSTALLINE DICLORHYDRATE OF AZOBICICLO 2.2.2 OCT - 3 - ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.
UY26177A1 (en) POLYMORPHOS OF A AZOBICICLO CITRATE (2.2.2) OCT-3- CRYSTALLINE ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS.
TR200601092T1 (en) New oral pharmaceutical formulations containing the active ingredient irbesartan.
AR045997A1 (en) STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF AZETIDINE
ECSP003510A (en) POLYMORPHOS OF A AZOBICICLO CITRATE (2,2,2) OCT - 3 - CRYSTALLINE ILAMINE AND ITS PHARMACEUTICAL COMPOSITIONS
PA8577801A1 (en) T1249 PEGILATED POLYPEPTIDE
AR005730A1 (en) FORM OF FANCICLOVIR, PROCEDURE FOR PREPARING IT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS AND THE USE OF SUCH FORM -FANCICLOVIR MONOIDRATE.
DE50311479D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING OXCARBAZEPINE WITH CONTROLLED ACTIVE INGREDIENTS
PE20040066A1 (en) NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF A Na CANAL BLOCKER
ECSP993181A (en) PROCEDURE FOR THE PREPARATION OF A HIGH PURITY COMPOSITION OF (7ALFA, 17ALFA) - 17 - HIDROXI-7-19-NOR-17- PREGN-5 (10) -EN -20-IN-3-ONA